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Objective: This study aims to evaluate the reliability and validity of neuropathic pain
assessment tools among Chinese patients with painful diabetic peripheral neuropathy
(PDPN).
Methods: One hundred patients with PDPN and 70 patients with non-neuropathic pain were
recruited from five grade III general hospitals in Guangzhou. Pain was assessed using the
Leeds Assessment of Neuropathic Symptoms and Signs (LANSS), Douleur Neuropathique 4
questionnaire (DN4), and Brief Pain Inventory for Painful Diabetic Peripheral Neuropathy
(BPI-DPN). Reliability was evaluated by internal consistency of the Cronbach's a coefficient
and Guttman split-half. Construct validity was analyzed by factor analysis and Spearman
correlation coefficients. Sensitivity and specificity were also assessed.
Results: The Cronbach's a coefficients of the LANSS, DN4, and BPI-DPN were 0.735, 0.750,
and 0.898, respectively. The Guttman split-half coefficients of the LANSS, DN4, and BPI-
DPN were 0.660, 0.726, and 0.849, respectively. The cumulative contributions of the
LANSS, DN4, and BPI-DPN to the total variance were 61.945%, 57.010%, and 66.056%,
respectively. The items of the LANSS, DN4, and BPI-DPN presented high factorial loads,
ranging from 0.387 to 0.841, 0.137 to 0.948, and 0.487 to 0.953, respectively. The LANSS and
DN4 exhibited sensitivities of 58.0% and 82.7%, respectively, and specificity of 97.1%.
Conclusions: The LANSS or DN4 can be used to detect neuropathic pain in Chinese patients
with PDPN. The BPI-DPN can be employed to monitor the effectiveness of pain
intervention.
Copyright © 2016, Chinese Nursing Association. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).Nursing Association.
g Association. Production and hosting by Elsevier B.V. This is an open access article under
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Diabetesmellitus (DM) is a common chronic disease and could
lead to diabetic peripheral neuropathy (DPN) [1]. DPN could
affect up to one-third of adults with diabetes [2]. Symptoms of
DPN include numbness, burning, pins and needles, and
sometimes allodynia. Painful diabetic peripheral neuropathy
(PDPN) is caused by abnormalities of the peripheral nervous
system in patients with diabetes [3]. The prevalence of PDPN
varies from 14.0% to 65.3% [4,5]. China has the highest human
population worldwide; of which, approximately 114 million
patients suffer from DM [6]. However, the prevalence of PDPN
in China has been rarely investigated.
PDPN affects the quality of life of patients, and the pain
severity of this disease is associated with anxiety and
depression [2,7,8]. Patients with PDPN exhibit significantly
higher healthcare resource utilization and costs than patients
with diabetes only [9]. Early detection of the presence of PDPN
contributes to treatment outcome. In addition, effective pain
assessment tools can be used to diagnose PDPN.
PDPN is difficult to diagnose. Gold diagnostic criteria for
PDPN have not been established clinically. Assessment tools
can be used to distinguish PDPN from other types of pain.
Several neuropathic pain assessment tools are available and
include the most widely used Leeds Assessment of Neuro-
pathic Symptoms and Signs (LANSS), Douleur Neuro-
pathique 4 questionnaire (DN4), and Brief Pain Inventory for
Painful Diabetic Peripheral Neuropathy (BPI-DPN). The
LANSS was developed by Bennett [10] and has been trans-
lated into Portuguese [11,12], Spanish [13,14], Turkish [15,16],
and other languages. The Chinese version of the LANSS was
translated and validated by Li et al. [17]. This version is reli-
able and valid. The DN4was designed by a French pain expert
group in 2005 [18] and has been translated into Arabic [19],
Dutch [20], Greek [21], and several other languages. However,
the Chinese version of the DN4 has not been reported. The
LANSS and DN4 are used to differentiate neuropathic pain
from non-neuropathic pain, but not for Chinese patients
with PDPN specifically. The Brief Pain Inventory (BPI) was
developed by Cleeland and Ryan [22], and the Chinese
version of this tool is widely used to assess acute, chronic,
and cancer pain. The BPI-DPN was revised by Zelman et al.
[23] to assess patients with PDPN, but this version has not
been reported in China.
This study aims to evaluate the reliability and validity of
the LANSS, DN4, and BPI-DPN among Chinese patients with
PDPN.2. Methods
2.1. Sample
A convenience sample was recruited at inpatient and outpa-
tient departments of endocrinology, inpatient department of
pain, and outpatient department of orthopedics from five
grade III general hospitals in Guangzhou from May 2014 to
January 2015. Inclusion criteria were as follows: a) age  18; b)
complaint of pain for over 3 months (persistent and/orrecurrent pain); c) having one of the following diagnosis:
neuropathic pain (PDPN), or non-neuropathic pain (low back
pain, myofascial pain syndrome, ankylosing spondylitis,
shoulder arthritis, headache, osteoporosis, carpal tunnel
syndrome, rib cartilage inflammation, osteoarthritis, etc.); and
d) willing and able to complete the questionnaire. The exclu-
sion criteria included the presence of neuropathic pain from
other causes or with mixed pain, history of foot ulcers or se-
vere comorbidities or lower limb amputation, and inability to
communicate and complete the questionnaire.
Based on sample size estimation, 100 subjects were
required for a two-sided test with 80% power of the test (1  b)
at a significance level a of 0.05. In previous studies, sample
sizes ranged from 42 to 123 and from 52 to 80 for neuropathic
pain and non-neuropathic pain, respectively. On the basis of
sample size estimation and previous studies, the sample sizes
for neuropathic pain (PDPN) and non-neuropathic pain used
for the present study were 100 and 70, respectively.
2.2. Measures
2.2.1. Leeds assessment of neuropathic symptoms and signs
(LANSS)
The LANSS [10] was developed to distinguish neuropathic pain
from nociceptive pain. The LANSS consists of pain question-
naire and sensory testing with seven items, and the highest
overall score is 24. Pain questionnaire includes sensations,
such as pricking, tingling, pins and needles, skin discolor-
ation, light touch pain, electric shocks, jumping and bursting,
and feeling of altered skin temperature, including hot and
burning. Sensory testing includes allodynia and altered pin-
prick threshold. If the pain symptom is consistent with the
description, the subjects answer “yes,” and the items are
scored 5, 5, 3, 2, 1, 5, and 3, respectively. If the pain symptom is
inconsistent, the subjects answer “no,” and the item is scored
0. The cut-off value is 12. If the total score is 12, neuropathic
mechanisms could contribute to the pain experienced by the
patient. The Chinese version of the LANSS used in this study
was translated by Li et al. with a Cronbach's a value of 0.824;
this version exhibits high sensitivity, specificity, and positive
and negative predictive values (>80%) [17].
2.2.2. Douleur neuropathique 4 questionnaire (DN4)
The DN4 [18] consists of four questionnaires in two parts,
namely, interview and examination, of the patient with a total
of 10 items. DN4-interview questions include burning, painful
cold, electric shocks, tingling, pins and needles, numbness,
and itching. Examination of the patient includes hypoesthesia
to touch, hypoesthesia to prick, and brushing. Each item is
scored “yes” or “no.” Each “yes” item is scored 1, and “no” is
scored 0, with a total possible score of 10. The cut-off value is
4. Total score 4 indicates neuropathic pain. The Chinese
version of the DN4 was translated by the first author and
another nursing master candidate and then back-translated
by the corresponding author.
2.2.3. Brief pain inventory for painful diabetic peripheral
neuropathy (BPI-DPN)
The Brief Pain Inventory (BPI) [22] includes pain intensity and
pain interference on a 0e10 numeric rating scale (NRS). Pain
i n t e r n a t i o n a l j o u r n a l o f nu r s i n g s c i e n c e s 3 ( 2 0 1 6 ) 1 3 9e1 4 5 141intensity is assessed as worst pain, least pain, average pain in
the last 24 h, and current pain. The pain interference includes
general activity, mood, walking ability, normal work, relations
to other people, sleep, and enjoyment of life during the past
24 h. The BPI-DPN is a revision of the BPI to phrase all items
with “due to diabetes.” The BPI-DPN was used to assess the
pain intensity and pain interference of patients with PDPN in
this study.Table 1 e Demographic and clinical data of patients.
Item PDPN (n ¼ 100) NNP (n ¼ 70) P2.3. Study procedures
Human subject ethics review was approved by the institu-
tional review boards. Two master students and one regis-
tered nurse were trained to conduct assessments
independently. A training session was provided, where in-
formation on pain assessment, definition of neuropathic
pain, clinical signs and symptoms of patients with PDPN, and
use of the three study tools was discussed to the data col-
lectors. Patients who met the inclusion criteria were
approached voluntarily, and informed consent was obtained
prior to participation. The same person performed data
collection, and all the tools were completed at one time in the
same order (LANSS, DN4, and BPI-DPN).
Demographic characteristics (gender, age, and education),
diagnosis (diabetes, pain-related diseases, and other chronic
diseases), life style and self-management (smoking and
drinking), and physical examination results including height,
weight, and blood pressure, were collected. Data on duration
of diabetes, family history of diabetes, history of hyperten-
sion, most recent laboratory test results (blood glucose and
blood lipids), and clinical treatment regimen were also
collected from patients with PDPN.
In this study, we defined DPN as “having diagnosis of DPN
from the medical history, or the presence of neuropathic
symptoms/signs, or abnormal results of monofilament test.”
PDPN was defined as average daily pain intensity of 4
(moderate or severe pain) in the 0e10 numeric rating scale in
the legs including the feet or hands in the last 48 h or
when patients were taking medication for their current pain
because of DPN [24]. The diagnoses of the non-neuropathic
pain and DPN were based on patient's medical record
by the physician. PDPN was confirmed through clinical
examination.Age (year) 59.32 ± 10.44 60.16 ± 15.52 0.694
Gender 0.013
Male (%) 49 (49.0) 21 (30.0)
Female (%) 51 (51.0) 49 (70.0)
Height (m) 1.63 ± 0.09 1.59 ± 0.74 0.006
Weight (kg) 62.09 ± 11.09 59.24 ± 9.24 0.076
BMI (kg/m2) 23.38 ± 3.35 23.39 ± 3.21 0.982
Education 0.883
8 years (%) 51 (52.6) 37 (52.9)
>8 years (%) 46 (47.4) 33 (47.1)
Smoking (%) 32 (32.3) 6 (8.6) <0.001
Drinking (%) 34 (34.3) 6 (8.6) <0.001
NRS scores 5.06 ± 2.35
BMI, body mass index; NNP, non-neuropathic pain; PDPN, painful
diabetic peripheral neuropathy; NRS, numeric rating scale.2.4. Statistical analysis
Analyses were performed using SPSS 13.0. Demographic and
clinical information were described using mean (standard
deviation, SD) for quantitative variables and percentage for
categorical variables. Comparisons between quantitative data
used independent sample t-test, and categorical data were
analyzed using Chi-square test. Reliability was evaluated by
internal consistency of Cronbach's a coefficient and Guttman
split-half. Construct validity was analyzed by factor analysis
(principal component analysis) and Spearman correlation
coefficients. The Kaiser-Meyer-Olkin (KMO) measure and
Bartlett's test of sphericity were used for factor analysis.
Sensitivity and specificity were also assessed.3. Results
3.1. Subjects
A total of 170 patients aged 23e90 years, with a mean age of
59.67 ± 12.77 years, were recruited in this study; of the pa-
tients, 70 were male (41.2%), and 100 were female (58.8%). One
hundred (58.8%) and 70 (41.2%) patients suffered PDPN and
non-neuropathic pain, respectively. In patients with non-
neuropathic pain, the diagnoses included osteoarthritis (36,
51.4%), low back pain (16, 22.9%), shoulder arthritis (5, 7.1%),
myofascial pain syndrome (5, 7.1%), rib cartilage inflammation
(2, 2.9%), carpal tunnel syndrome (2, 2.9%), headache (2, 2.9%),
ankylosing spondylitis (1, 1.4%), and osteoporosis (1, 1.4%).
Among patients with PDPN, 22 had a family history of dia-
betes, 33 with hypertension, and 5 had coronary heart dis-
eases. Regarding treatment for diabetes, 22 of the patients had
oral drugs, 20 were administered with insulin, and 56 were
given with oral drugs and insulin. The demographic and
clinical data of the patients are shown in Tables 1 and 2.
In patients with PDPN, the frequency of positive items of
the LANSS ranged from 28.0% to 99.0%, with top items, such as
sensations like pricking, tingling, pins and needles (99.0%);
electric shocks, jumping, and bursting (93.0%); and altered
pin-prick threshold (59.0%). The frequency of positive items of
the DN4 ranged from 14.3% to 82.7%, with top items, such as
pins and needles (82.7%), tingling (81.6%), electric shocks
(76.5%), and numbness (72.4%). In patients with non-
neuropathic pain, the frequency of positive items of the
LANSS and DN4 ranged from 0 to 18.6% and 1.4e22.9%,
respectively. This result is significantly lower than that in
patients with PDPN (P < 0.001).3.2. Reliability
The Cronbach's a coefficient of the LANSS was 0.735 in pa-
tients with PDPN, and the Guttman split-half coefficient was
0.660. If each itemwere deleted, the Cronbach's a of the LANSS
would range from 0.657 to 0.746.
Table 2 e Clinical information of patients with PDPN.
Item Mean ± SD
Duration of diabetes (years) 9.30 ± 6.84
Systolic blood pressure (mmHg) 136.80 ± 19.38
Diastolic blood pressure (mmHg) 80.85 ± 11.56
Fasting plasma glucose (mmol/L) 8.09 ± 2.98
2 h postprandial plasma (mmol/L) 11.68 ± 4.17
HbA1c (%) 8.71 ± 2.29
Total cholesterol (mmol/L) 4.90 ± 1.30
Triglycerides (mmol/L) 1.98 ± 1.61
LDL-cholesterol (mmol/L) 2.82 ± 0.99
HDL-cholesterol (mmol/L) 1.26 ± 0.69
PDPN, painful diabetic peripheral neuropathy; LDL, low density li-
poprotein; HDL, high density lipoprotein.
Table 4 e Factor loading matrix of DN4 after rotation.
Item Factor
1 2 3 4
Burning 0.156 0.181 0.724
Painful cold 0.137 0.383
Electric shocks 0.726 0.203 0.112
Tingling 0.559 0.466 0.286
Pins and needles 0.709 0.150 0.395
Numbness 0.242 0.948 0.102
Itching 0.283
Hypoesthesia to touch 0.215 0.484
Hypoesthesia to prick 0.101 0.157 0.551
Brushing 0.174 0.111 0.585
DN4, Douleur neuropathique 4 questionnaire.
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Guttman split-half coefficient was 0.726. If each item were
deleted, the Cronbach's a of theDN4would range from0.680 to
0.769.
The Cronbach's a coefficient of the BPI-DPN was 0.898, and
the Guttman split-half coefficient was 0.849. If each itemwere
deleted, the Cronbach's a of the BPI-DPN would range from
0.882 to 0.896.
3.3. Validity
The results showed the suitability of the LANSS (KMO
value ¼ 0.735) and the significance of the adopted procedure
(Bartlett's test with a value of 386.435, P < 0.001). The principal
component analysis of the LANSS showed that the eigen-
values of two components were greater than 1, and the cu-
mulative proportion of variance explained was 61.945%. The
items of the LANSS presented high factorial loads, ranging
from 0.387 to 0.841. The lowest factorial load was “skin
discoloration” (0.387) (Table 3). The highest Spearman corre-
lation coefficient between the items was “pricking, tingling,
and pins and needles” (0.825). The lowest item was “feeling of
altered skin temperature” (0.380).
The results showed the suitability of the DN4 (KMO
value ¼ 0.743) and the significance of the adopted procedure
(Bartlett's test with a value of 388.345, P < 0.001). The principal
component analysis of the DN4 indicated that the eigenvalues
of three components were greater than 1, and the cumulative
variance accounted for 57.010% of the total variance. The
items of the DN4 presented high factorial loads, ranging from
0.137 to 0.948. The lowest factorial load was “painful cold”Table 3 e Factor loading matrix of LANSS after rotation.
Item Factor
1 2
Pricking, tingling, pins, and needles 0.841 0.323
Skin discoloration 0.387
Light touch pain 0.790
Electric shocks, jumping, and bursting 0.800
Feeling of altered skin temperature 0.417
Allodynia 0.808
Altered pinprick threshold 0.497
LANSS, Leeds assessment of neuropathic symptoms and signs.(0.137) (Table 4). The highest Spearman correlation coefficient
between the items was “pins and needles” (0.794), and the
lowest item was “painful cold” (0.226).
The results showed the suitability of the BPI-DPN (KMO
value ¼ 0.825) and the significance of the adopted procedure
(Bartlett's test with a value of 706.942, P < 0.001). The principal
component analysis of the BPI-DPN indicated that the eigen-
values of two components were greater than 1, and the cu-
mulative variance accounted for 66.056% of the total variance.
The items of the BPI-DPN presented high factorial loads,
ranging from 0.487 to 0.953 (Table 5).
The sensitivities of the LANSS (12) and DN4 (4) were
58.0% and 82.7%, respectively. The specificity of both tests was
97.1%.
3.4. Pain severity and pain interference in patients with
PDPN
The results using the BPI-DPN showed that patients with
PDPN experienced considerable pain, which affected their
lives. For pain intensity, the mean scores of the worst, least,
average, and current pain were 7.18 ± 1.70, 4.05 ± 2.34,
5.70 ± 1.76, and 5.06 ± 2.35, respectively. For pain interference,
the mean scores for general activity, mood, walking ability,
normal work, relations with other people, sleep, and enjoy-
ment of life were 6.57 ± 2.67, 6.05 ± 2.53, 6.62 ± 2.79, 6.88 ± 3.05,
5.03 ± 2.54, 7.29 ± 2.15, and 6.40 ± 2.78, respectively. The ma-
jority levels of the worst pain, least pain, average pain in the
past 24 h, and current pain are higher than the medium level.
In addition, the pain interference in patients increased with
pain intensity.4. Discussion
The findings show that the LANSS, DN4, and BPI-DPN could be
used for Chinese patients with PDPN.
In previous studies, the Cronbach's a coefficients of the
LANSS varied in different samples, as follows: Portuguese,
0.67 [11] and 0.78 [12]; and Chinese, 0.82 [17]. Similar to pre-
vious studies, the present study showed that the Cronbach's a
coefficient of the LANSS in patients with PDPN was 0.735. For
the DN4, the Cronbach's a coefficient was 0.750, which is lower
Table 5 e Factor loading matrix of BPI-DPN after rotation.
Item Factor
1 2
Worst pain 0.408 0.487
Least pain 0.838
Average pain 0.953
Current pain 0.734
General activity 0.727
Mood 0.643
Walking ability 0.788
Normal work 0.840
Relations with other people 0.667 0.383
Sleep 0.400 0.371
Enjoyment of life 0.696 0.340
BPI-DPN, brief pain inventory for painful diabetic peripheral
neuropathy.
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higher than that in Arabic (0.63) [19] and Portuguese (0.71) [26].
The Cronbach's a coefficient of the BPI-DPN was 0.898, which
is lower than that in previous study reported by Zelman et al.
[23].
The construct validity of the items of the instruments was
verified with factor analysis by principal component analysis
with rotation. The LANSS extracted two factors, consistent
with the scale structure. The results obtained for the DN4 are
lower than the original version that used nine factors. The
high factorial loads of the DN4 are lower than that reported in
Portuguese version (ranging from 0.502 to 0.817) [26]. Different
extraction techniques could explain these results. The item
“skin discoloration” in the LANSS and “painful cold” in the
DN4 had the lowest factorial load, indicating that these items
need to be adjusted. The high factorial load of each item in the
BPI-DPN was above 0.4, indicating mutually independent
factors. The construct validity of the BPI-DPN was ideal.
Sensitivity and specificity were also analyzed. The sensi-
tivity of the LANSS was 58.0%, which is lower than those re-
ported in previous studies (80.17e93.00%) [12e15]. However,
Hallstrom and Norrbrink [27] showed that the sensitivity was
36% when used in spinal cord injury patients. In patients with
neck/upper limb pain [28] and failed back surgery syndromes
[29], the sensitivity was lower than that in patients with PDPN
in the present study. The specificity of the LANSS was 97.1%.
The results are higher than those obtained using Portuguese
[12] and Turkish [15] versions as well as in patients suffering
from neck/upper limb pain [28], cancer pain [30, 31], and failed
back surgery syndromes [29], but lower than the Spanish
version [13] and in patients with spinal cord injury [27].
The sensitivity and specificity of the DN4 were 82.7% and
97.1%, respectively. The results are higher than those of the
original [18], Dutch [20], and Spanish [32] versions, aswell as in
patients suffering from cancer pain [31] and failed back sur-
gery syndromes [29]. In the original version of the DN4 [18], the
sensitivity and specificity were 82.9% and 89.9%, respectively;
this finding confirmed that this tool can efficiently distinguish
neuropathic pain from non-neuropathic pain. In the Dutch
version of the DN4, the sensitivity and specificity were rela-
tively low, with values of 75% and 79%, respectively [20]. In theSpanish version of the DN4, the sensitivity and specificity
were as low as 79.8% and 78%, respectively [32]. Meanwhile,
the sensitivity of the DN4 is lower than those in Greek [21] and
Persian [25] versions, as well as in patients with spinal cord
injury [27]; however, the specificity is higher than that in
previous studies. Spallone et al. [33] showed that the DN4
displayed sensitivity of 80% and specificity of 92% in painful
diabetic polyneuropathy. Extending to diverse population, we
chose patients with non-neuropathic pain for comparison.
The apparent diversity may be due to the clinical character-
istics of the patients, such as inclusion of individuals with
mixed pain, as well as pain classification and differences in
clinical diagnosis.
In patients with PDPN, complaints, including tingling, pins
and needles, and sensations like electric shocks, were
assessed by the LANSS and DN4; these findings are consistent
with the clinical signs and symptoms based on the definition
of neuropathic pain. Although the DN4 and LANSS were
developed as a screening tool for detecting neuropathic pain,
these instruments are not considered as diagnostic tools and
cannot be employed for medical diagnosis.
On average, patients' pain was not well-controlled, with
mean pain scores of 5 or higher. PDPN seriously affected the
life of the patients. Hence, pain control needs to be improved.
In 2011, the American Academy of Neurology released the
evidence-based guideline “Treatment of painful diabetic
neuropathy; ” this guideline recommends the use of tricyclic
antidepressants and anticonvulsants for painful diabetic
neuropathy [34]. A Chinese translation of the clinical guide-
lines on how to use these drugs treating painful diabetic
neuropathy patients is also available; however, implementa-
tion of the guideline in clinical practice was not reliable and
may influence the effectiveness of treatments for PDPN and
patient outcome.
Previous studies reported that neuropathic pain of patients
could lead to inability to walk, reduced productivity, and
reluctance to participate in social activities [35]. Particularly,
the inability to walk of some patients could result in social
dysfunction. Neuropathic pain assessment tools, such as the
LANSS, DN4, and BPI-DPN, could be used by healthcare pro-
fessionals to elucidate the extent of pain severity and its
interference on patients with PDPN. These tools can also be
used to develop appropriate interventions for alleviating the
symptoms and improving the quality of life of patients.
This study presents several limitations that should be
considered in interpreting the results. First, patients with
mixed pain were excluded, which may influence the results
because these patients are probably themost difficult group to
diagnose with or without neuropathic pain. In addition, these
patients could have a neuropathic component that contrib-
utes to their pain. Second, the same person performed data
collection without blinding, and all tools were completed at
one time. This factor may also affect the results.5. Conclusions
The LANSS, DN4, and BPI-DPN could be used to diagnose
Chinese patients with PDPN. Comparison shows that the DN4
exhibits higher diagnostic sensitivity than the LANSS. The
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patients with PDPN. The BPI-DPN could also be used to
monitor the effectiveness of pain intervention.Author contributions
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